United Therapeutics Corporation

UTHR12 Jan 2025
Healthcare
$362.94
0.00 (-0.45%)
Lowest Today
$358.8
Highest Today
$365.33
Today’s Open
$362.94
Prev. Close
$366.61
52 Week High
$417.82
52 Week Low
$208.62
To Invest in United Therapeutics Corporation

United Therapeutics Corporation

Healthcare
UTHR12 Jan 2025
0.00 (-0.45%)
1M
3M
6M
1Y
5Y
Low
$358.8
Day’s Range
High
$365.33
358.8
52 Week Low
$208.62
52-Week Range
52 Week High
$417.82
208.62
1 Day
-
1 Week
+2.84%
1 month return
+1.22%
3 month return
+2.47%
6 month return
+13.32%
1 Year return
+66.77%
3 Years return
+77.07%
5 Years return
+323.77%
10 Years return
-
Institutional Holdings
BlackRock Inc
11.91
Vanguard Group Inc
9.88
Wellington Management Company LLP
7.1
venBio Select Advisor LLC
6.4
State Street Corp
5.01
Renaissance Technologies Corp
4.83
iShares Core S&P Mid-Cap ETF
3.26

Market Status

Fundamentals
Market Cap
16367.12 mln
PB Ratio
2.68
PE Ratio
16.11
Enterprise Value
13440.63 mln
Total Assets
7167 mln
Volume

Company Financials

Fund house & investment objective

Company Information
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Organisation
United Therapeutics Corporation
Employees
1168
Industry
Biotechnology
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step